Abivax announces closing of $747.5 million public offering

Abivax announces closing of $747.5 million public offering paris, france, july 28, 2025 – 10:15 p.m. (cest) – abivax sa (euronext paris: fr0012333284 – abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 american depositary shares (“adss”), each representing one ordinary share, €0.01 nominal value per share (each an “ordinary share”), of the company, in the united states (the “offering”), which includes the full exercise of the underwriters' option to purchase additional adss (the “underwriters' option”).
ABVX Ratings Summary
ABVX Quant Ranking